Description: As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases
Home Page: www.editasmedicine.com
EDIT Technical Analysis
11 Hurley Street
Cambridge,
MA
02141
United States
Phone:
617 401 9000
Officers
Name | Title |
---|---|
Mr. James C. Mullen | Exec. Chairman |
Ms. Michelle Robertson | CFO, Principal Accounting Officer, Treasurer & Assistant Sec. |
Dr. Mark S. Shearman | Exec. VP & Chief Scientific Officer |
Dr. Bruce E. Eaton Ph.D. | Exec. VP & Chief Bus. Officer |
Dr. Gilmore O'Neill | Pres & CEO |
Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member |
Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member |
Dr. J. Keith Joung M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member |
Dr. David R. Liu Ph.D. | Co-Founder & Scientific Advisory Board Member |
Mr. Harry R. Gill III | Sr. VP of Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.7176 |
Price-to-Sales TTM: | 26.3844 |
IPO Date: | 2016-02-03 |
Fiscal Year End: | December |
Full Time Employees: | 264 |